Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALGS logo ALGS
Upturn stock ratingUpturn stock rating
ALGS logo

Aligos Therapeutics Inc (ALGS)

Upturn stock ratingUpturn stock rating
$7.21
Last Close (24-hour delay)
Profit since last BUY-8.62%
upturn advisory
Consider higher Upturn Star rating
BUY since 13 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ALGS (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $90.33

1 Year Target Price $90.33

Analysts Price Target For last 52 week
$90.33Target price
Low$3.76
Current$7.21
high$46.8

Analysis of Past Performance

Type Stock
Historic Profit 40.1%
Avg. Invested days 41
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 44.09M USD
Price to earnings Ratio -
1Y Target Price 90.33
Price to earnings Ratio -
1Y Target Price 90.33
Volume (30-day avg) 3
Beta 2.69
52 Weeks Range 3.76 - 46.80
Updated Date 06/30/2025
52 Weeks Range 3.76 - 46.80
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -17.47

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -6187.46%

Management Effectiveness

Return on Assets (TTM) -38.74%
Return on Equity (TTM) -60.44%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -85899285
Price to Sales(TTM) 13.48
Enterprise Value -85899285
Price to Sales(TTM) 13.48
Enterprise Value to Revenue 0.38
Enterprise Value to EBITDA 0.57
Shares Outstanding 5314800
Shares Floating 2941280
Shares Outstanding 5314800
Shares Floating 2941280
Percent Insiders 10.44
Percent Institutions 65.64

Analyst Ratings

Rating 2
Target Price 90.33
Buy 1
Strong Buy 2
Buy 1
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Aligos Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Aligos Therapeutics, Inc. was founded in 2018 and is focused on developing novel therapeutics to address liver diseases. They've progressed through various preclinical and clinical stages, with a focus on chronic hepatitis B virus (CHB) and nonalcoholic steatohepatitis (NASH).

business area logo Core Business Areas

  • Chronic Hepatitis B (CHB): Development of multiple therapeutic modalities aimed at achieving functional cure for CHB.
  • Nonalcoholic Steatohepatitis (NASH): Development of therapies targeting key pathways involved in NASH pathogenesis.

leadership logo Leadership and Structure

The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure involves research, development, clinical, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • ALG-010133: An antisense oligonucleotide designed to reduce HBsAg, a key viral protein in CHB. Currently in clinical trials. Limited market share at this stage (pre-revenue). Competitors: Roche (RG6346), GSK (bepirovirsen).
  • Other CHB programs: Aligos has several other pre-clinical programs targeting different aspects of the HBV lifecycle. Market share is currently zero, as these are pre-clinical. Competitors: Gilead, Assembly Biosciences.
  • NASH programs: Aligos had a NASH program targeting thyroid hormone receptor beta but has since shifted focus to CHB. No current market share. Prior competitors included: Madrigal Pharmaceuticals, Viking Therapeutics.

Market Dynamics

industry overview logo Industry Overview

The liver disease therapeutics market is experiencing significant growth, driven by increasing prevalence of CHB and NASH. High unmet medical need and growing awareness are fueling research and development efforts.

Positioning

Aligos is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for liver diseases. They are competing with larger pharmaceutical companies and smaller biotech firms.

Total Addressable Market (TAM)

The CHB market is estimated to be worth billions of dollars annually. NASH's TAM is also significant and growing. Aligos is positioned to capture a portion of these markets with successful products.

Upturn SWOT Analysis

Strengths

  • Strong scientific expertise in liver disease
  • Diverse pipeline of therapeutic candidates
  • Experienced management team

Weaknesses

  • Limited financial resources compared to larger competitors
  • Clinical trial risks and uncertainties
  • Dependence on successful development of lead programs

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Advancements in liver disease research and diagnostics
  • Expansion into new therapeutic areas within liver disease

Threats

  • Competition from established players
  • Regulatory hurdles and delays
  • Failure of clinical trials

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • VIR
  • ROCHE
  • GSK
  • ABUS

Competitive Landscape

Aligos faces intense competition from larger pharmaceutical companies with established market presence. Their competitive advantage lies in their differentiated therapeutic approaches and strong scientific expertise.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by pipeline development and clinical trial progress.

Future Projections: Future growth is dependent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary.

Recent Initiatives: Recent initiatives include advancing clinical trials for ALG-010133 and exploring partnerships for other programs.

Summary

Aligos Therapeutics is a clinical-stage biotech company with a focus on liver diseases. They possess strong scientific expertise and a diverse pipeline, but face significant clinical and financial risks. Positive clinical trial results are crucial for future success. They need to be aware of larger competitors and possible cashflow issues.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Company Website
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is an estimation.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aligos Therapeutics Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2020-10-16
CEO, President & Chairman of the Board Dr. Lawrence M. Blatt MBA, Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 70
Full time employees 70

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.